Geneva, Switzerland, 14 MARCH 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today its planned participation at upcoming industry conferences this season, as follows:
BIO-Europe Spring
20 – 22 March 2017, CCIB Convention Centre, Barcelona, Spain
Selexis will participate in the partnering program and is conference sponsor.
For more information, please visit: https://ebdgroup.knect365.com/bioeurope-spring
Cell Line Development & Engineering
24 – 27 April 2017, Amsterdam RAI Exhibition and Convention Centre, Amsterdam, The Netherlands
Selexis is a sponsor and exhibitor of the conference.
For more information, please visit: https://lifesciences.knect365.com/cell-line-congress
PEGS Summit
1 – 5 May 2017, Seaport World Trade Center, Boston, MA, USA
Selexis Chief Scientific Officer Pierre-Alain Girod, PhD, will present “CHO Cell Line Engineering for Enhanced Productivity and Stability” on Wednesday, 3rd May at 12:25 p.m. ET as part of the Engineering Antibodies Stream. Selexis Scientific Advisory Board member Sir Gregory Winter will be the plenary speaker. Additionally, Selexis is a conference sponsor.
For more information, please visit: http://www.pegsummit.com
European Society for Animal Cell Technology (ESACT)
14 – 17 May 2017, SwissTech Convention Center, Lausanne, Switzerland
Selexis representatives will attend and participate in the program.
For more information, please visit: http://www.esact2017.com
BIO International Convention
19 – 22 June 2017, San Diego Convention Center, San Diego, CA USA
Selexis will be exhibiting at this conference and participating in the partnering program.
For more information, please visit: http://www.convention.bio.org/2017
About Selexis SA
Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 95 partners worldwide, nearly 80 drug products in clinical manufacturing and two commercial products utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.
